Contraception practices and counseling for adolescent and young adult women with sickle cell disease (SCD) vary by the healthcare…
Articles by Steve Bryson, PhD
Oxbryta (voxelotor) has been granted marketing approval in Great Britain to treat hemolytic anemia in people ages 12 and…
To mark World Sickle Cell Day, Marja Hurley, a University of Connecticut (UConn) physician-researcher, has been awarded nearly $3 million…
Exagamglogene autotemcel (exa-cel), an experimental gene-editing cell therapy, increased fetal hemoglobin levels and prevented vaso-occlusive crises (VOCs) in 31…
Graphite Bio’s GPH101, an investigational gene-editing therapy that aims to correct the genetic mutation that causes sickle cell…
Disrupting a specific area of the gene that encodes for adult hemoglobin — which is faulty in people with…
A naturally-occurring protein called hemopexin, also an investigational therapy for acute vaso-occlusive crises (VOCs) in sickle cell disease…
The United Arab Emirates (UAE) Ministry of Health has approved Endari (L-glutamine) for sickle cell disease (SCD), according to…
Dosing will soon start in a Phase 1/2 trial of GPH101, an experimental gene-editing therapy designed to correct the genetic…
Red blood cell biomarkers may predict sickle cell disease (SCD) severity and the risk of vaso-occlusive crisis, according to…